Coronavirus
Moderna Stock Offering Is to Price at $76 Per Share

(Bloomberg) — Moderna Inc. plans to raise as much as $1.3 billion through a sale of shares to fund manufacturing of a coronavirus vaccine seen as one of the frontrunners in the race for immunization against the widening pandemic.
The U.S. biotechnology firm will sell 17.6 million shares priced at $76 a piece, according to a statement Tuesday. The price represents a 5% discount to Monday’s closing price.
Morgan Stanley is the sole book-running manager for the offering that allows underwriters to buy an additional 2.64 million shares, the statement said. Bloomberg reported the share sale plan earlier.
Shares jumped 20% on Monday after the company revealed positive early results from its experimental vaccine for Covid-19, capping off a 309% rally this year.
Moderna’s vaccine is seen as one of the most promising candidates for immunization against the pathogen that has sickened over 4.8 million people worldwide and killed over 318,000 since it first emerged in China last December. A successful vaccine is a crucial step toward lifting lockdowns, easing social distancing measures and safely reopening economies gutted by strict containment efforts.
The promising results that Moderna reported were just a sample from the small, first study designed to look at the safety of the shot in human volunteers. But they showed no major safety worries – a key first hurdle since a vaccine would be given to millions of otherwise healthy people.
“This is a very good sign that we make an antibody that can stop the virus from replicating,” Moderna Chief Executive Officer Stephane Bancel said in an interview Monday. The data “couldn’t have been better.”
The biotech firm is moving ahead with plans for a larger test to pick a dose of the vaccine and further study its effectiveness, as well as a phase 3 test that will administer the vaccine to many thousands of patients.
The safety profile appeared to be good, Bancel said, and the reactions were typical of vaccines. Three patients who got a high dose of the vaccine had more severe side effects, according to a company presentation. That dose won’t be used in later trials.
Side effects seen in the trial included fatigue, fever, muscle pains and headache but all the symptoms resolved within a day.
-
News2 months ago
Offer Price, Overview, Investors: Here’s Everything You Need to Know About Asyad Shipping’s Mega IPO
-
OER Magazines1 month ago
OER, February 25
-
Automotive2 months ago
[REVIEW] A Legend Reinvented: The Nissan Patrol Y63 Blends Heritage with Modern Mastery
-
Alamaliktistaad Magazines1 month ago
Al-iktisaad, February 2025
-
Energy2 months ago
Dubai Supreme Council of Energy Unveils 5th Emirates Energy Award 2023–2025 in Muscat
-
News2 months ago
Oil Prices Rise as Investors Assess New US Tariff Threats
-
Banking & Finance2 months ago
Alizz Islamic Bank Partners with Visa to Launch Premium Shari’a-Compliant Card Solutions
-
News2 months ago
Middle East Emerging as a Key Destination for Sports Tourism